Company Overview - Pluxee is a global leader in Employee Benefits and Engagement, operating in 29 countries with a focus on Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [2] - The company serves over 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants, supported by more than 5,000 team members and advanced technology [2] - Pluxee has been in business for over 45 years, emphasizing positive community impact, employee wellbeing, and environmental sustainability [2] Liquidity Contract Summary - As of December 31, 2024, the liquidity account held 200,439 Pluxee N.V. ordinary shares valued at €5,878,911 [4] - During the period from July 1, 2024, to December 31, 2024, the company purchased 972,323 ordinary shares worth €19,626,472 across 6,377 transactions and disposed of 848,300 ordinary shares worth €17,195,841 across 5,661 transactions [4] - In the previous half-yearly report as of June 30, 2024, the liquidity account held 59,130 Pluxee N.V. ordinary shares valued at €8,621,644 [4] - From January 31, 2024, to June 30, 2024, the company purchased 723,308 ordinary shares worth €19,930,588 across 5,132 transactions and disposed of 719,315 ordinary shares worth €19,933,554 across 4,627 transactions [4] - The liquidity account started with €10,000,000 as of January 31, 2024 [4]

Core Insights - The company reported a strong start to Fiscal Q1 2025, achieving total revenues of 289 million euros, representing a 13.2% organic growth year-on-year, driven by robust performance in Employee Benefits and Float revenue [2][9][6] Financial Performance - Operating revenue reached 249 million euros, with a 12.1% organic growth compared to the previous year, primarily fueled by Employee Benefits which saw a 14.9% organic growth [10][12] - Float revenue amounted to 40 million euros, reflecting a 20.9% organic growth year-on-year, supported by an increasing Float base and improved average investment yield [11][6] - Total business volumes issued in the first quarter reached 6.5 billion euros, up from 6.1 billion euros in the same period last year [5] Regional Performance - Continental Europe generated operating revenue of 105 million euros, showing a 9.7% organic growth, while Latin America reported 98 million euros with an 11.1% organic growth [15][16] - The Rest of the World segment achieved 46 million euros in operating revenue, reflecting a significant 20.0% organic growth, driven by increased adoption of Pluxee solutions [17] Business Segments - Employee Benefits accounted for 212 million euros in operating revenue, with a 14.9% organic growth, indicating strong commercial dynamics and client retention [12][33] - Other products and services generated 37 million euros, experiencing a slight decline of 2.6% organically, impacted by a contract discontinuation in Chile [13][31] M&A and Strategic Initiatives - The company is actively pursuing M&A opportunities, including the acquisition of Benefício Fácil, a leader in employee mobility benefits in Brazil, expected to enhance organic growth [20][19] - The partnership with Santander in Brazil is progressing well, with approximately 90% of business volume migration completed, contributing to significant new client wins [21][19] Outlook - The company reaffirms its financial objectives for Fiscal 2025 and 2026, targeting low double-digit organic revenue growth and further expansion of the Recurring EBITDA margin [24][27]

Core Viewpoint - Protalix BioTherapeutics is making significant progress in its development pipeline and commercial partnerships, particularly with Chiesi Global Rare Diseases, to enhance treatment options for patients with rare diseases like Fabry disease [1][5][10]. Group 1: Company Developments - Protalix has achieved important milestones in 2024, including the validation of a less frequent dosing regimen for pegunigalsidase alfa by the European Medicine Agency [1]. - The company has successfully completed a Phase I First-in-Human clinical trial for PRX-115, demonstrating its potential as a safe and effective treatment for uncontrolled gout, with plans to advance to Phase II trials in the second half of 2025 [10]. - Protalix has repaid all outstanding convertible notes, resulting in a debt-free status, which strengthens its financial position for ongoing operations [12]. Group 2: Product Pipeline - The development pipeline includes proprietary recombinant therapeutic proteins targeting established pharmaceutical markets, such as PRX-115 for gout and PRX-119 for NETs-related diseases [5][11]. - Elfabrio®, the company's second product, received FDA and EMA approval in May 2023, marking a significant achievement in its product portfolio [16]. Group 3: Partnerships and Collaborations - Protalix's collaboration with Chiesi Farmaceutici S.p.A. is crucial for the global development and commercialization of Elfabrio, highlighting the importance of strategic partnerships in the company's growth [5][1]. - The partnership aims to reduce the treatment burden for patients with Fabry disease, showcasing a commitment to patient-centered care [1].

Company Overview - Pluxee is a global player in employee benefits and engagement, operating in 29 countries [3] - The company offers a broad range of solutions across Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [3] - Pluxee has over 5,400 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3] - The company has been a trusted partner for over 45 years, focusing on positive impacts for stakeholders and supporting employee wellbeing [3] Annual General Meeting Highlights - The Annual General Meeting of Shareholders was held on December 18, 2024, in Amsterdam-Schiphol [1] - All resolutions on the agenda were approved, including the adoption of financial statements for Fiscal 2024 [2] - A dividend distribution of EUR 0.35 per ordinary share was approved, with the ex-dividend date set for December 20, 2024, record date on December 23, 2024, and payment date on December 24, 2024 [2] - The meeting was broadcast live, and detailed voting results will be available on the Pluxee Group website [2]

Financial Performance - Protalix BioTherapeutics reported Q3 2024 revenues of $17.8 million, a 75% increase from $10.2 million in Q3 2023, primarily driven by a $6.8 million increase in sales to Chiesi and a $1.1 million increase in sales to Pfizer[9]. - Total revenues for the nine months ended September 30, 2024, were $35,181,000, an increase from $30,309,000 for the same period in 2023, representing a growth of approximately 16.5%[27]. - Net income for Q3 2024 was approximately $3.2 million, or $0.04 per share, compared to a net loss of $1.9 million in Q3 2023[17]. - The net loss for the period was $3,562,000, compared to a net income of $14,356,000 for the same period in 2023, indicating a significant decline in profitability[27]. - Operating income for the nine months ended September 30, 2024, was a loss of $3,292,000, contrasting with an operating income of $16,075,000 for the same period in 2023[27]. - The company reported a basic loss per share of $0.05 for the nine months ended September 30, 2024, compared to earnings of $0.22 for the same period in 2023[27]. Expenses - The cost of goods sold for Q3 2024 was $8.4 million, a 71% increase from $4.9 million in Q3 2023, attributed to higher sales volumes[11]. - Research and development expenses decreased by 19% to approximately $3.0 million in Q3 2024, down from $3.7 million in Q3 2023, due to the completion of the Fabry clinical program[13]. - Selling, general and administrative expenses were $2.6 million in Q3 2024, a 30% decrease from $3.7 million in Q3 2023, primarily due to reduced salary and professional fees[14]. - Research and development expenses for the nine months ended September 30, 2024, were $8,846,000, down from $13,991,000 for the same period in 2023, a decrease of approximately 36.5%[27]. - Selling, general and administrative expenses decreased to $9,194,000 for the nine months ended September 30, 2024, from $10,816,000 in the same period in 2023, a reduction of about 15%[27]. Cash and Assets - Cash and cash equivalents stood at approximately $27.4 million as of September 30, 2024[16]. - Cash and cash equivalents increased to $27,409,000 as of September 30, 2024, up from $23,634,000 at the end of 2023[26]. - Total current assets decreased to $47,853,000 as of September 30, 2024, down from $69,932,000 at the end of 2023, reflecting a decline of approximately 31.6%[26]. - Total liabilities decreased to $29,126,000 as of September 30, 2024, compared to $50,865,000 at the end of 2023, a reduction of about 42.5%[26]. Clinical Development - The company completed all eight cohorts of its Phase I clinical trial for PRX-115, with 64 subjects enrolled, and is planning to initiate a Phase II trial in the second half of 2025[2][3]. - Preliminary results showed that PRX-115 effectively reduced plasma uric acid levels, maintaining levels below 6.0 mg/dL for up to 12 weeks at the highest dose[4]. - Protalix's development pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, among others[22]. Debt Management - The company repaid all outstanding principal and interest on its 7.50% Senior Secured Convertible Promissory Notes in September 2024, financed entirely with available cash[8].

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive U.S. FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product for Gaucher disease, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix announced that Dror Bashan, the Company's President and CEO, will present live at the Life Sciences Investor Forum on September 19, 2024 [1] - The event will allow real-time interaction with investors, and an archived webcast will be available for those unable to attend live [2] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, such as: - PRX–115: a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout [5] - PRX–119: a plant cell-expressed long-action DNase I for NETs-related diseases [5] - The company's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Partnerships - Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [5]

Core Viewpoint - Protalix BioTherapeutics has successfully repaid all outstanding convertible notes, achieving a debt-free status and strengthening its financial position for ongoing operations [1][2]. Financial Position - The company has eliminated a total of $78.0 million in convertible notes, which had previously contributed to its financing over the last decade [2]. - The repayment was financed entirely with available cash, indicating strong financial discipline and a robust balance sheet [1][2]. Company Overview - Protalix BioTherapeutics specializes in the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system [3]. - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based expression system [3]. Product Pipeline - Protalix has licensed the worldwide rights for taliglucerase alfa, its first product for Gaucher disease, to Pfizer Inc., retaining full rights in Brazil [3]. - The company’s second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency (EMA) in May 2023 [3]. - Protalix is collaborating with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [4]. - The development pipeline includes PRX–115 for uncontrolled gout and PRX–119 for NETs-related diseases, among other proprietary therapeutic proteins [4].

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update. "In the second quarter, Protalix ha ...

Core Viewpoint - Protalix BioTherapeutics, Inc. will release its financial results for Q2 2024 and provide a business and clinical update on August 14, 2024 [1] Group 1: Financial Results and Updates - The company will host a conference call with investors to discuss financial results and recent corporate and regulatory developments [2] - The conference call is scheduled for August 14, 2024, at 8:30 a.m. EDT [3] Group 2: Conference Call and Webcast Details - Toll-free and international call details are provided for participants [3] - A webcast will be available, and participants are encouraged to access the call 15 minutes early [4] Group 3: Company Overview - Protalix specializes in the development and commercialization of recombinant therapeutic proteins using its ProCellEx plant cell-based expression system [5] - The company has FDA approval for its first product, taliglucerase alfa, for Gaucher disease, and its second product, Elfabrio®, was approved in May 2023 [5] - Protalix has partnered with Chiesi Farmaceutici for the global development of Elfabrio and has a pipeline of therapeutic proteins targeting various diseases [6]

About Aleš Linhart, DSc, FESC Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale ma ...